Zobrazeno 1 - 10
of 33
pro vyhledávání: ''
Ewing sarcoma (EWS) is a pediatric malignancy driven by the EWSR1-FLI1 fusion protein formed by the chromosomal translocation t(11;22). The small molecule TK216 was developed as a first-in-class direct EWSR1-FLI1 inhibitor and is in phase II clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2910bc69b7bfe3cd5647904a712cedfd
https://doi.org/10.1101/2021.11.19.469182
https://doi.org/10.1101/2021.11.19.469182
Autor:
Lihua He, Hong Dang, Scott H. Randell, Rhianna E. Lee, Minges Jt, Lisa C. Morton, Castle Na, Adam J. Kimple, Theile Jw, Michael R. Knowles, Catherine A. Lewis, Gallant Sc, Teresa M. Mascenik
With the approval of elexacaftor/tezacaftor/ivacaftor (trade name Trikafta), the vast majority of people with cystic fibrosis (CF) are eligible for CF transmembrane conductance regulator (CFTR) modulator therapy. Remaining individuals have premature
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2de0779d2aa54a95f1251c245e574cd9
https://doi.org/10.1101/2021.09.28.462149
https://doi.org/10.1101/2021.09.28.462149
Autor:
Thale Kristin Olsen, Ninib Baryawno, David B. Sykes, Conny Tümmler, Cecilia Dyberg, Ida Hed Myrberg, Jan Koster, Jörg Otte, Jelena Milosevic, Ellen M. Westerhout, Rogier Versteeg, Bethel Embaie, Per Kogner, Adele Alchahin, John Inge Johnsen
Despite intensive therapy, children with high-risk neuroblastoma are at risk of treatment failure. We applied a pan-cancer, multi-omic system approach to evaluate metabolic vulnerabilities in human neuroblastoma. By combining metabolomics, CRISPR scr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::358b75db96afddca5ee089fccc09c6b2
https://doi.org/10.1101/2021.09.25.461496
https://doi.org/10.1101/2021.09.25.461496
Autor:
Angelo M. De Marzo, Radhika A. Patel, Gunes Guner, Harrison Tsai, Minh-Tam Pham, Ruedi Aebersold, Tiannan Guo, Akshay Bhamidipati, David M. Esopi, Jessica Hicks, Ajay Vaghasia, Michael C. Haffner, Nicolas Wyhs, Jin-Yih Low, Nicole Castagna, Srinivasan Yegnasubramanian, William G. Nelson
BACKGROUNDResistance to androgen deprivation therapies is a major driver of mortality in advanced prostate cancer. Therefore, there is a need to develop new pre-clinical models that allow the investigation of resistance mechanisms and the assessment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16685d7af4fcbe84d72fcf445bd5999a
https://doi.org/10.1101/2021.07.04.450352
https://doi.org/10.1101/2021.07.04.450352
Autor:
Klamova H, Brezinova J, Obr A, Ransdorfova S, Cermakova K, Zackova M, Machackova-Lopotova T, Mitrovsky O, Myslivcova D
Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the presence of a BCR-ABL oncogene. Despite the high performance of treatment with tyrosine kinase inhibitors (TKI), about 30 % of patients develop resistance to ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35f830a49f90e4732f0a20452a3fc024
https://doi.org/10.1101/2021.06.28.450156
https://doi.org/10.1101/2021.06.28.450156
While all-trans retinoic acid (ATRA) is an essential therapy in the treatment of acute promyelocytic leukemia (APL), an aggressive subtype of acute myeloid leukemia, nearly 20% of APL patients are resistant to ATRA. As no biomarkers for ATRA resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c78a092ff17657ddbe355c2a0b989036
https://doi.org/10.1101/2021.04.25.441378
https://doi.org/10.1101/2021.04.25.441378
Autor:
Amaja Lujambio, Serif Senturk, Larry Glassman, Polona Safaric Tepes, Vilma Jimenez Sabinina, Debjani Pal, Madison Miller, David Zeltsman, Ingrid Ibarra, Michael Esposito, Gregory J. Hannon, Trine Lindsted, Jiahao Huang, Kevin Hyman, Paul C. Lee, Raffaella Sordella, Navya Korimerla
Lung cancer remains the leading cause of cancer-related mortality worldwide, despite current advancements in research and therapeutics. Many patients diagnosed with lung cancer will develop resistance to chemotherapeutic agents. In the context of non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dea0ea56bd6368d97a7221bf53bbdd5
https://doi.org/10.1101/2021.01.06.425631
https://doi.org/10.1101/2021.01.06.425631
Publikováno v:
Cell Death and Disease, Vol 12, Iss 5, Pp 1-16 (2021)
Cell Death & Disease
Cell Death & Disease
Increasing evidence supports that ferroptosis plays an important role in tumor growth inhibition. Sorafenib, originally identified as an inhibitor of multiple oncogenic kinases, has been shown to induce ferroptosis in hepatocellular carcinoma (HCC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8d6d5c5cfd0b50c4ca64169e04ca162
https://doi.org/10.1101/2020.12.14.422655
https://doi.org/10.1101/2020.12.14.422655
Current therapies offer only a short relief for patients with pediatric glioblastoma (PED-GBM). Therefore, expanding treatment options for this fatal disease is of utmost importance. We found that PED-GBM cell lines, originated from diffuse intrinsic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85b8f7bddb070aa0ee9f475b81c98a60
https://doi.org/10.1101/2020.11.25.397497
https://doi.org/10.1101/2020.11.25.397497
Autor:
Spartaco Santi, Mattia Lauriola, Valerio Gelfo, Michelangelo Fiorentino, Gabriele D'Uva, Donatella Romaniello, Balazs Gyorffy, Martina Mazzeschi, Michela Sgarzi, Ruth H. Palmer, Carola Cavallo
In the last years, several efforts have been made to classify colorectal cancer (CRC) into well-defined molecular subgroups, representing the intrinsic inter-patient heterogeneity, known as Consensus Molecular Subtypes (CMSs). In this work, we perfor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dde604a6aa38bc897e123c464410415a
https://doi.org/10.1101/2020.10.07.307991
https://doi.org/10.1101/2020.10.07.307991